Nurix Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NRIX research report →
Range $20 – $41
Price Chart
About the company
Nurix Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
- CEO
- Arthur T. Sands
- IPO
- 2020
- Employees
- 317
- HQ
- Brisbane, CA, US
Get TickerSpark's AI analysis on NRIX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.40B
- P/E
- 5.49
- Fwd P/E
- 4.73
- PEG
- 0.04
- P/S
- 2.14
- P/B
- 1.59
- EV/EBITDA
- 2.64
- Div Yield
- 0.00%
- Gross Margin
- 86.50%
- Op Margin
- 41.27%
- Net Margin
- 42.01%
- ROE
- 49.34%
- ROIC
- 25.95%
Latest fiscal year · YoY change
- Revenue
- $83.98M+54.0%
- Gross Profit
- $65.12M+139.0%
- Op Income
- $-285,666,000
- Net Income
- $-264,457,000-36.6%
- EPS
- $-3.05-5.9%
- OCF Growth
- -44.5%
- FCF Growth
- -44.9%
- 52W High
- $28.23
- 52W Low
- $12.82
- 50D MA
- $22.31
- 200D MA
- $20.08
- Beta
- 1.80
- RSI (14)
- 21
- Avg Volume
- 2.46M
No earnings-call transcripts are available for NRIX yet.
- Free Float
- 95.2%
- Shares Outstanding
- 109.25M
- Float Shares
- 104.05M
of shares held by institutions
218 13F filers
Buy/sell ratio 0.54. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.80M | ▲ 30.89K |
| Vestal Point Capital, LP | 8.05M | ▲ 1.55M |
| Deep Track Capital, LP | 7.74M | ▲ 1.39M |
| Rubric Capital Management LP | 7.23M | ▲ 4.75M |
| Vanguard Group Inc | 5.95M | ▲ 1.46M |
| Price T Rowe Associates Inc | 5.44M | ▲ 2.15M |
| Morgan Stanley | 5.25M | ▲ 484.03K |
| Fmr LLC | 4.68M | ▼ 805.40K |
| Baker Bros. Advisors LP | 4.66M | 0 |
| Vanguard Capital Management LLC | 4.50M | ▲ 9.24K |
| State Street Corp | 4.43M | ▼ 248.57K |
| Perceptive Advisors LLC | 4.32M | ▲ 609.54K |
Held by 294 ETFs
Biggest fund positions in NRIX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | van Houte Hans | sell | 3,300 |
| Nov 4, 26 | van Houte Hans | sell | 1,469 |
| Nov 2, 26 | Ring Christine | other | 5,786 |
| Nov 2, 26 | Ring Christine | other | 5,786 |
| Nov 2, 26 | Ring Christine | sell | 9,527 |
| Nov 2, 26 | Ring Christine | sell | 1,075 |
| Nov 3, 26 | Ring Christine | sell | 6,113 |
| Oct 30, 26 | van Houte Hans | other | 3,573 |
| Oct 30, 26 | van Houte Hans | sell | 2,834 |
| Oct 30, 26 | van Houte Hans | other | 2,859 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NRIX coverage
Recent articles, reports, and earnings notes.
No research on NRIX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NRIX report →Nurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 Transcript
seekingalpha.com · Nov 17
Nurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical Officer
globenewswire.com · Nov 11
Nurix Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com · Nov 10
Nurix Therapeutics to Present New and Updated Data from Ongoing Phase 1a/1b Trial of Bexobrutideg (NX-5948) in Relapsed/Refractory CLL/SLL at the 68th ASH Annual Meeting and Exposition
globenewswire.com · Nov 5
Nurix Therapeutics Announces Sanofi's Decision to Discontinue Development of STAT6 Degrader SAR448272
globenewswire.com · Nov 3
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
seekingalpha.com · Oct 14
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
zacks.com · Oct 12
Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Oct 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.